Chiara Romagnani

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4869717/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	SARS-CoV-2 Nsp13 encodes for an HLA-E-stabilizing peptide that abrogates inhibition of NKG2A-expressing NK cells. Cell Reports, 2022, 38, 110503.	2.9	31
2	Type 1 innate lymphoid cells regulate the onset of Toxoplasma gondii-induced neuroinflammation. Cell Reports, 2022, 38, 110564.	2.9	16
3	A natural killer's hike through epigenetic landscapes. Science Immunology, 2021, 6, .	5.6	0
4	Multiplexed histology analyses for the phenotypic and spatial characterization of human innate lymphoid cells. Nature Communications, 2021, 12, 1737.	5.8	26
5	Extent of Cytomegalovirus Replication in the Human Host Depends on Variations of the HLA-E/UL40 Axis. MBio, 2021, 12, .	1.8	17
6	An inÂvitro platform supports generation of human innate lymphoid cells from CD34+ hematopoietic progenitors that recapitulate exÂvivo identity. Immunity, 2021, 54, 2417-2432.e5.	6.6	32
7	T-bet and RORα control lymph node formation by regulating embryonic innate lymphoid cell differentiation. Nature Immunology, 2021, 22, 1231-1244.	7.0	18
8	Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition). European Journal of Immunology, 2021, 51, 2708-3145.	1.6	198
9	Th1 responses in vivo require cell-specific provision of OX40L dictated by environmental cues. Nature Communications, 2020, 11, 3421.	5.8	13
10	NK cell receptor NKG2D enforces proinflammatory features and pathogenicity of Th1 and Th17 cells. Journal of Experimental Medicine, 2020, 217, .	4.2	25
11	c-FLIP is crucial for IL-7/IL-15-dependent NKp46+ ILC development and protection from intestinal inflammation in mice. Nature Communications, 2020, 11, 1056.	5.8	12
12	Editorial: In Memoriam of Professor Alessandro Moretta. Frontiers in Immunology, 2020, 11, .	2.2	0
13	In Situ Maturation and Tissue Adaptation of Type 2 Innate Lymphoid Cell Progenitors. Immunity, 2020, 53, 775-792.e9.	6.6	88
14	Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition). European Journal of Immunology, 2019, 49, 1457-1973.	1.6	766
15	The Central Nervous System Contains ILC1s That Differ From NK Cells in the Response to Inflammation. Frontiers in Immunology, 2019, 10, 2337.	2.2	31
16	c-Maf-dependent Treg cell control of intestinal TH17 cells and IgA establishes host–microbiota homeostasis. Nature Immunology, 2019, 20, 471-481.	7.0	138
17	Peptide-specific recognition of human cytomegalovirus strains controls adaptive natural killer cells. Nature Immunology, 2018, 19, 453-463.	7.0	319
18	CD96 expression determines the inflammatory potential of IL-9–producing Th9 cells. Proceedings of the United States of America, 2018, 115, F2940-F2949	3.3	36

CHIARA ROMAGNANI

#	Article	IF	CITATIONS
19	Stable lines and clones of long-term proliferating normal, genetically unmodified murine common lymphoid progenitors. Blood, 2018, 131, 2026-2035.	0.6	8
20	The AP-1-BATF and -BATF3 module is essential for growth, survival and TH17/ILC3 skewing of anaplastic large cell lymphoma. Leukemia, 2018, 32, 1994-2007.	3.3	70
21	Innate lymphoid cells in lung infection and immunity. Immunological Reviews, 2018, 286, 102-119.	2.8	42
22	Clonal expansion and compartmentalized maintenance of rhesus macaque NK cell subsets. Science Immunology, 2018, 3, .	5.6	41
23	The Role of Natural Killer Group 2, Member D in Chronic Inflammation and Autoimmunity. Frontiers in Immunology, 2018, 9, 1219.	2.2	31
24	Natural killer cell specificity for viral infections. Nature Immunology, 2018, 19, 800-808.	7.0	169
25	Boosting Type 2 Immunity: When OX40L Comes from ILC2s. Immunity, 2018, 48, 1067-1069.	6.6	5
26	Guidelines for the use of flow cytometry and cell sorting in immunological studies [*] . European Journal of Immunology, 2017, 47, 1584-1797.	1.6	505
27	About Training and Memory. Advances in Immunology, 2017, 133, 171-207.	1.1	61
28	OMIPâ€039: Detection and analysis of human adaptive NKG2C ⁺ natural killer cells. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2017, 91, 997-1000.	1.1	17
29	Adaptive Natural Killer Cells Integrate Interleukin-18 during Target-Cell Encounter. Frontiers in Immunology, 2017, 8, 1976.	2.2	19
30	Specific phenotype and function of CD56-expressing innate immune cell subsets in human thymus. Journal of Leukocyte Biology, 2016, 100, 1297-1310.	1.5	3
31	Adoptively transferred natural killer cells maintain long-term antitumor activity by epigenetic imprinting and CD4 ⁺ T cell help. Oncolmmunology, 2016, 5, e1219009.	2.1	61
32	Natural Killer (NK) Cell Functionality after human Spinal Cord Injury (SCI): protocol of a prospective, longitudinal study. BMC Neurology, 2016, 16, 170.	0.8	23
33	Critical Role of CD2 Co-stimulation in Adaptive Natural Killer Cell Responses Revealed in NKG2C-Deficient Humans. Cell Reports, 2016, 15, 1088-1099.	2.9	202
34	Differentiation of human innate lymphoid cells (ILCs). Current Opinion in Immunology, 2016, 38, 75-85.	2.4	71
35	Putting the brakes on ILC2 cells. Nature Immunology, 2016, 17, 43-44.	7.0	15
36	IL-10–producing forkhead box protein 3–negative regulatory TÂcells inhibit B-cell responses andÂare involved in systemic lupus erythematosus. Journal of Allergy and Clinical Immunology, 2016, 137, 318-321.e5.	1.5	37

CHIARA ROMAGNANI

#	Article	IF	CITATIONS
37	Innate Lymphoid Cells Type 3. , 2016, , 156-168.		о
38	Clonal Expansion and Long-Term Persistence of Rhesus Macaque NK Cells with an Adaptive Phenotype. Blood, 2016, 128, 549-549.	0.6	0
39	ICOS regulates the pool of group 2 innate lymphoid cells under homeostatic and inflammatory conditions in mice. European Journal of Immunology, 2015, 45, 2766-2772.	1.6	80
40	Group 3 innate lymphoid cells (ILC3s): Origin, differentiation, and plasticity in humans and mice. European Journal of Immunology, 2015, 45, 2171-2182.	1.6	153
41	The 3 major types of innate and adaptive cell-mediated effector immunity. Journal of Allergy and Clinical Immunology, 2015, 135, 626-635.	1.5	562
42	Recognition Strategies of Group 3 Innate Lymphoid Cells. Frontiers in Immunology, 2014, 5, 142.	2.2	67
43	IL-21 Is a Central Memory T Cell–Associated Cytokine That Inhibits the Generation of Pathogenic Th1/17 Effector Cells. Journal of Immunology, 2014, 193, 3322-3331.	0.4	48
44	Human Cytomegalovirus Drives Epigenetic Imprinting of the IFNG Locus in NKG2Chi Natural Killer Cells. PLoS Pathogens, 2014, 10, e1004441.	2.1	224
45	Human RORÎ ³ t+CD34+ Cells Are Lineage-Specified Progenitors of Group 3 RORÎ ³ t+ Innate Lymphoid Cells. Immunity, 2014, 41, 988-1000.	6.6	132
46	Tracking in vivo dynamics of NK cells transferred in patients undergoing stem cell transplantation. European Journal of Immunology, 2014, 44, 2822-2834.	1.6	21
47	NK/DC crosstalk in immunosurveillance: A broken relationship caused by WASPâ€deficiency. European Journal of Immunology, 2014, 44, 958-961.	1.6	4
48	<scp>NK</scp> cells gain higher <scp>IFN</scp> â€i³ competence during terminal differentiation. European Journal of Immunology, 2014, 44, 2074-2084.	1.6	94
49	Human CD1c+ dendritic cells secrete high levels of IL-12 and potently prime cytotoxic T-cell responses. Blood, 2013, 122, 932-942.	0.6	300
50	RORÎ ³ t+ Innate Lymphoid Cells Acquire a Proinflammatory Program upon Engagement of the Activating Receptor NKp44. Immunity, 2013, 38, 1223-1235.	6.6	166
51	Signatures of Human NK Cell Development and Terminal Differentiation. Frontiers in Immunology, 2013, 4, 499.	2.2	131
52	A Converse 4-1BB and CD40 Ligand Expression Pattern Delineates Activated Regulatory T Cells (Treg) and Conventional T Cells Enabling Direct Isolation of Alloantigen-Reactive Natural Foxp3+ Treg. Journal of Immunology, 2012, 189, 5985-5994.	0.4	108
53	The early cellular signatures of protective immunity induced by live viral vaccination. European Journal of Immunology, 2012, 42, 2363-2373.	1.6	62

54 Does Innate Immunity Get Old?. , 2012, , 25-36.

CHIARA ROMAGNANI

#	Article	IF	CITATIONS
55	CD62L expression identifies a unique subset of polyfunctional CD56dim NK cells. Blood, 2010, 116, 1299-1307.	0.6	249
56	The Emerging Role of HLA-E-Restricted CD8 ⁺ T Lymphocytes in the Adaptive Immune Response to Pathogens and Tumors. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-8.	3.0	81
57	Education of hyporesponsive NK cells by cytokines. European Journal of Immunology, 2009, 39, 2548-2555.	1.6	38
58	Cytokine-induced human IFN-γ–secreting effector-memory Th cells in chronic autoimmune inflammation. Blood, 2009, 113, 1948-1956.	0.6	58
59	HLA-E and HLA-E-Bound Peptides: Recognition by Subsets of NK and T Cells. Current Pharmaceutical Design, 2009, 15, 3336-3344.	0.9	45
60	CD56brightCD16â^' Killer Ig-Like Receptorâ^' NK Cells Display Longer Telomeres and Acquire Features of CD56dim NK Cells upon Activation. Journal of Immunology, 2007, 178, 4947-4955.	0.4	430
61	Multidirectional interactions are bridging human NK cells with plasmacytoid and monocyte-derived dendritic cells during innate immune responses. Blood, 2006, 108, 3851-3858.	0.6	69
62	Activation of human NK cells by plasmacytoid dendritic cells and its modulation by CD4+ T helper cells and CD4+ CD25hi T regulatory cells. European Journal of Immunology, 2005, 35, 2452-2458.	1.6	127
63	Post-thymic in vivo proliferation of naive CD4+ T cells constrains the TCR repertoire in healthy human adults. European Journal of Immunology, 2005, 35, 1987-1994.	1.6	136
64	The small subset of CD56brightCD16– natural killer cells is selectively responsible for both cell proliferation and interferon-l³ production upon interaction with dendritic cells. European Journal of Immunology, 2004, 34, 1715-1722.	1.6	178
65	HLA-E–restricted recognition of human cytomegalovirus by a subset of cytolytic T lymphocytes. Human Immunology, 2004, 65, 437-445.	1.2	42
66	Comparative analysis of NK- or NK-CTL-mediated lysis of immature or mature autologous dendritic cells. European Journal of Immunology, 2003, 33, 3427-3432.	1.6	16
67	Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: a study on 593 infusions. Bone Marrow Transplantation, 2003, 31, 687-693.	1.3	89
68	NK-CTLs, a novel HLA-E-restricted T-cell subset. Trends in Immunology, 2003, 24, 136-143.	2.9	86
69	HLA-E-restricted recognition of cytomegalovirus-derived peptides by human CD8+ cytolytic T lymphocytes. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 10896-10901.	3.3	175
70	Identification of HLA-E-specific alloreactive T lymphocytes: A cell subset that undergoes preferential expansion in mixed lymphocyte culture and displays a broad cytolytic activity against allogeneic cells. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 11328-11333.	3.3	87
71	Increased risk of leukemia relapse with high dose cyclosporine after allogeneic marrow transplantation for acute leukemia: 10 year follow-up of a randomized study. Blood, 2001, 98, 3174-3174.	0.6	31
72	p75/AIRM1 and CD33, two sialoadhesin receptors that regulate the proliferation or the survival of normal and leukemic myeloid cells. Immunological Reviews, 2001, 181, 260-268.	2.8	47

#	Article	IF	CITATIONS
73	Preferential Th1 profile of T helper cell responses in X-linked (Bruton′s) agammaglobulinemia. European Journal of Immunology, 2001, 31, 1927-1934.	1.6	40
74	The analysis of the natural killer-like activity of human cytolytic T lymphocytes revealed HLA-E as a novel target for TCR α/β-mediated recognition. European Journal of Immunology, 2001, 31, 3687-3693.	1.6	91
75	Pre-emptive therapy of acute graft-versus-host disease: a pilot study with antithymocyte globulin (ATG). Bone Marrow Transplantation, 2001, 28, 1093-1096.	1.3	45
76	Surface expression and function of p75/AIRM-1 or CD33 in acute myeloid leukemias: Engagement of CD33 induces apoptosis of leukemic cells. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 5764-5769.	3.3	100
77	Regulation of myeloid cell proliferation and survival by p75/AIRM1 and CD33 surface receptors. Advances in Experimental Medicine and Biology, 2001, 495, 55-61.	0.8	4
78	Engagement of p75/AIRM1 or CD33 inhibits the proliferation of normal or leukemic myeloid cells. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 15091-15096.	3.3	137